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Abstract
Context: Treatment of X-linked hypophosphatemia (XLH) with active vitamin D metabolites and
phosphate can partially correct skeletal deformities. It is unclear if therapy influences the
occurrence of two major long-term morbidities in XLH: enthesopathy and dental disease.
Objective: To investigate the relationship between treatment and enthesopathy and dental disease
in adult XLH patients.
Design: Observational and cross-sectional.
Setting: Academic medical center’s hospital research unit.
Participants: 52 XLH patients aged >= 18 at time of study.
Interventions: None
Main outcome measures: Number of enthesopathy sites identified by radiographic skeletal
survey and dental disease severity (>5 or <=5 dental abscesses), identified historically.
Methods: Associations between proportion of adult life and total life with treatment and number
of enthesopathy sites were assessed using multiple linear regression, while associations between
these exposure variables and dental disease severity were assessed using multiple logistic
regression. All models were adjusted for confounding factors.
Results: Neither proportion of adult nor total life with treatment was a significant predictor of
extent of enthesopathy. In contrast, both of these treatment variables were significant predictors
of dental disease severity (multivariate-adjusted global p-value =0.0080 and =0.0010
respectively). Participants treated 0% of adulthood were more likely to have severe dental disease
than those treated 100% of adulthood (adjusted OR 25 [95% CI 1.2-520]). As proportion of total
life with treatment increased, the odds of having severe dental disease decreased (multivariateadjusted p-value for trend=0.015).
Conclusions: Treatment in adulthood may not promote or prevent enthesopathy; however it may
be associated with lower risk of experiencing severe dental disease.
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Introduction
X-linked hypophosphatemia (XLH), the most common form of heritable rickets, is a
dominant disorder of phosphate homeostasis whose prevalence is estimated at 1 in 20,000 (1).
The pathophysiology of this disease is related to loss of function mutations in the phosphateregulating endopeptidase gene (PHEX) (2). PHEX is normally expressed in bone and teeth and its
disruption results in increased circulating levels of fibroblast growth factor 23 (FGF23) (3).
FGF23 acts in an endocrine manner at the kidney to both decrease renal tubular reabsorption of
phosphate and renal 1-α-hydroxylase activity resulting in the combined findings of
hypophosphatemia and inadequate levels of circulating 1,25(OH)2D observed in XLH (2).
Hypophosphatemia, low 1,25(OH)2D, and perhaps independently, elevated FGF23 and
disruption of PHEX contribute to the broad range of severity in the skeletal and dental
morbidities in XLH(1). Common skeletal abnormalities observed in XLH include bowing of the
legs, anteromedial rotation and torsion of the tibiae, and poor bone mineralization (osteomalacia)
with resultant growth retardation and bone disease (4). However, later in life, patients often
experience mineralization of tendons and ligaments (enthesopathy) (1). Dental morbidities
include delayed dentition and dental abscesses with the latter continuing throughout adult life (1).
The current standard of therapy for XLH is a regimen of active vitamin D metabolites,
usually calcitriol, and phosphate beginning at time of diagnosis and continuing to growth
completion (1). The administration of these therapies intermittently increases serum phosphate,
providing necessary mineral to the growing skeleton and thereby partially correcting leg
deformities (5). After growth completion, the rationale for therapy is directed toward
symptomatic osteomalacia and prevention or correction of fractures or insufficiency fractures (1).
It remains to be established whether therapy affects the other major adult sequelae of XLH,
particularly enthesopathy and dental disease.
Continuing conventional treatment into adulthood has been controversial both because its
efficacy is not well studied, and because it is burdensome and potentially toxic (4). Long-term
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therapy with calcitriol and phosphate may result in hyperparathyroidism, hypercalcemia,
hypercalciura, nephrocalcinosis, and in extreme cases, chronic kidney disease (4). However, if
monitored for safety, treatment has been shown to improve certain features of the disease,
including pain and osteomalacia (6). Therefore, it is of great clinical importance to establish the
effect of therapy on enthesopathy and dental disease during adult life. Using data from a
relatively large cohort of XLH patients this study examined the association between conventional
XLH therapy and two significant morbidities experienced in the adult phase of the disease:
enthesopathy and dental abscess formation.
Materials and Methods
Subjects and Design
The study sample included 52 XLH patients age 18 or older. Patients were offered
participation during clinical visits to the Yale Bone Center or upon referral from other physicians.
The study population consisted of 18 males and 34 females. Exclusion criteria included presence
of other diseases likely to impact bone and mineral metabolism (e.g. renal, hepatic,
gastrointestinal disorders, and malignancy), treatment with estrogen or bisphosphonates, and
pregnancy.
Data Collection
Biochemical measures reflecting pathophysiology or therapeutic toxicity were obtained
for each study participant. Serum PTH was measured as area under the curve from samples
obtained at 4-hour intervals for 8 consecutive intervals using a mid-region assay (7). FGF23 was
measured as a single value from a fasting morning sample using the Kainos intact ELISA kit
(kindly provided by Kyowa Hakko Kirin Pharma, Inc.). Participant characteristics, including age
at onset of treatment, years with treatment, frequency of pain medication use, previous
osteotomies, and number of dental abscesses were obtained from both medical records and
extensive questioning of history. Research nursing staff measured participant height using a
stadiometer and weight using a calibrated scale. These measurements were used to calculate both
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height z-scores and body mass index (BMI) with the latter calculated as kilogram body weight
per height in meters squared. Participants were genotyped by Sanger sequencing to determine the
nature of their PHEX mutations. We categorized frame-shift and splice-site mutations as “severe”
and missense and point mutations as “non-severe”. Sites of enthesopathy were determined via
skeletal survey examined by a radiologist. The specific anatomic sites surveyed included
shoulders, elbows, hands, wrists, pelvis, knees, ankle, and thoracic-lumbar spine.
Exposures of Interest
The primary exposure of interest in this study was treatment with calcitriol (or high dose
vitamin D) and phosphate. Because of the importance of age in the natural history of this disease,
treatment exposure was assessed as a proportion of both total years of life and total years of adult
life. All years of life age 18 and over were counted towards adult life. Proportion of adult life
with treatment was calculated by dividing total years of treatment in adult life by total years of
adult life. This exposure variable was categorized into three levels based on the distribution of the
sample: 0.0 of adult life with treatment, greater than 0.0 but less than 1.0 of adult life with
treatment, and 1.0 of adult life with treatment. Proportion of total life with treatment was
calculated by dividing total years of treatment throughout life by total years of life. This exposure
variable was categorized into four levels based on the quartile distribution of the sample: <0.436,
0.436-<0.588, 0.588-0.881, 0.881<=1.0.
Outcomes of Interest
There were two primary outcomes of interest in this study: number of sites of
enthesopathy identified on an a priori designed skeletal survey, and number of dental abscesses
experienced per participant. Enthesopathy was assessed as a continuous variable. Dental disease
severity was assessed as a dichotomous variable: a history of >5 dental abscesses (“severe”
dental disease) versus a history of ≤ 5 dental abscesses (“non-severe” dental disease).
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Statistical Analysis
The association between each of our two primary exposure variables, proportion of adult
life and proportion of total life with treatment, and number of sites of enthesopathy was assessed
using multiple linear regression. The association between each of our two primary exposure
variables and dental disease severity was assessed using multiple logistic regression, modeling
the odds of having “severe” versus “non-severe” dental disease. Because of the importance of age
in the natural history of XLH, all models included age as a covariate. Age-adjusted models
included only the primary exposure variable of interest and age. In addition, the following
variables were assessed as potential confounders of the relationship between the respective
exposure variables and enthesopathy: sex, body mass index, mutation severity, PTHauc, and
FGF23. Covariates were retained in the model if their addition resulted in a 10% or greater
change in the parameter estimate for the primary exposure variable. Both fully adjusted models
for enthesopathy included age, sex, body mass index, mutation severity, and PTHauc. Both fully
adjusted models for dental disease included age, sex, and mutation severity. For all models
assessing proportion of life with treatment as the primary predictor, proportion of childhood with
treatment was also included as a covariate. Proportion of childhood with treatment was assessed
as a dichotomous variable: <0.80 of childhood versus >= 0.80 of childhood. P-values for trend
and global p-values were obtained for the primary predictor variables. All analyses were
performed using the statistical software package SAS 9.3.
Descriptive Statistics
Table 1 presents selected participant characteristics across three groups defined by
proportion of adult life with treatment. The mean age of the study sample was 39 years. The total
years of childhood treatment (before age 18) was relatively similar across all groups with an
overall sample average of 13.9 years. For the entire sample (as well as for each treatment
category) there were approximately 35% males and 65% females, consistent with the X-linked
dominant mode of inheritance. The majority of participants had severe vs. not severe mutations
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(65% vs. 25%). On average, 1.8 sites of enthesopathy were identified per patient. Average sites of
enthesopathy across the three proportional treatment categories did not differ notably. A majority
of our sample had severe dental disease versus non-severe dental disease (61.5% vs. 38.5%).
There were notable differences in dental disease severity across the adult life treatment
categories: 75% of those participants with no (0%) treatment during adult life had severe dental
disease while only 47% of those treated throughout all (100%) of adult life had severe dental
disease.
Enthesopathy
Table 2 presents both age-adjusted and multivariate-adjusted multiple linear regression
models of the relationship between proportion of adult life with treatment, as well as other
predictors, and number of sites of enthesopathy. We found that after adjusting for age, proportion
of adult life with treatment was not a significant predictor of number of sites of enthesopathy
(age-adjusted global p-value=0.96) and this finding remained after adjusting for confounders
(multivariate-adjusted global p-value=0.90). We did, however, find that age, BMI, and sex were
important predictors of the number of sites of enthesopathy. Age and body mass index were
positively associated with number of sites of enthesopathy (p<0.001 for each covariate). Female
sex was negatively associated with number of sites of enthesopathy (p=0.0080). We found that
females on average had 0.42 less sites of enthesopathy compared to males. We found borderline
significant positive association between PTHauc and number of sites of enthesopathy. In contrast,
mutation severity and proportion of treatment in childhood did not predict extent of enthesopathy
(p=0.42 and p=0.10 respectively). Table 3 presents age-adjusted and multivariate-adjusted
multiple linear regression models of the relationship between proportion of total life, as well as
other predictors, and number of sites of enthesopathy for the purposes of comparison. Proportion
of total life with treatment was also not a significant predictor of this outcome (age-adjusted
global p-value= 0.18; multivariate-adjusted global p-value=0.90). Results for other covariates
were similar to those seen in the model for proportion of adult life with treatment: age, BMI, and
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PTHauc were positively associated with number of sites of enthesopathy while female sex was
negatively associated with this outcome. However, the PTHauc association did not achieve
borderline significance in this model (p=0.10).
Dental Disease
Table 4 presents age-adjusted and multivariate-adjusted multiple logistic regression
models of the relationship between proportion of adult life with treatment, as well as other
predictors, and severity of dental disease. In both the age-adjusted and multivariate-adjusted
analyses, proportion of adult life with treatment was negatively associated with the odds of
having severe dental disease (global p-value=0.038 and 0.0080 respectively). After adjustment
for confounders, we found a borderline significant trend between increasing proportion of adult
life with treatment and decreasing odds of having severe dental disease (p-value for trend=0.066).
Those who were not treated at all during adult life were more likely to experience severe dental
disease than those who were treated for 100% of adulthood (adjusted OR 25 [95% CI 1.2-520]).
We found that age was a significant predictor of dental disease severity: for a 1 year increase in
age, the odds of having severe dental disease increased by 10% (OR: 1.1 [95% CI 1.0-1.2]).
Furthermore, we found that sex was a borderline significant predictor of dental disease severity
(p=0.061). Females had lower odds of experiencing severe dental disease compared to males (OR
0.15 [95% CI 0.020-1.1]). Those treated for less than 80% of childhood had higher odds of
experiencing severe dental disease compared to those treated for 80% or greater of childhood
(OR: 7.2 [95% CI 0.71-73]). Mutation severity was positively associated with severity of dental
disease: those with severe mutations had higher odds of experiencing severe dental disease
compared to those who did not have severe mutations (OR 3.9 [95% CI 0.63-25)]. These
relationships did not, however, achieve statistical significance. Table 5 presents age-adjusted and
multivariate-adjusted multiple linear regression models of the relationship between proportion of
total life, as well as other predictors, and severity of dental disease. Proportion of total life with
treatment was negatively associated with severity of dental disease (age-adjusted global p-value
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0.012; multivariate-adjusted global p-value 0.0010). As proportion of total life with treatment
increased, the odds of having severe dental disease decreased (age-adjusted p-value for
trend=0.046; multivariate-adjusted p-value for trend=0.015). Results for other covariates were
similar to those seen in the model for proportion of adult life with treatment: age and mutation
severity were positively associated with dental disease severity while female sex was negatively
associated with this outcome.
Discussion
The results of this study suggest that the extension of treatment for XLH with calcitriol
and phosphate into adulthood neither prevents nor promotes enthesopathy, but may prove
beneficial for the prevention of dental abscesses. Most previous work on the efficacy of this
therapeutic regimen has focused on the pediatric XLH population and as a result there is currently
not an established consensus regarding treatment of the adult patient. Moreover, the limited
studies in the adult XLH population have not assessed the effect of therapy on the specific
outcomes that were the focus of our study. Sullivan et al. conducted a prospective study of the
relationship between phosphate and calcitriol treatment and biochemical, clinical, and histological
responses in 16 adult XLH patients (7). They found that 87% of participants reported significant
improvement in musculoskeletal symptoms and osteoid thickness was significantly reduced as
well (7). Costa et al. assessed 5 “adult” patients (defined as >15 years of age) and 6 children with
XLH and found that skeletal improvements were most pronounced in, but not limited to, the prepubescent patients (8). Although these studies examined certain skeletal outcomes, neither
assessed enthesopathy as an outcome and the sample sizes were too small to assess possible
associations with treatment duration and skeletal outcomes.
Although enthesopathy is well described in XLH patients, previous studies have not
examined treatment effects on this complication. More numerous reports of dental complications
exist; however a beneficial effect of medical therapy on dental outcomes has yet to be established
(4). Furthermore, it is established that the management of dental abscesses via pulpectomy and
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root canal often fails (11). Moreover, one dental abscess tends to predict the occurrence of future
abscesses (10). In light of this information, our findings suggest that conventional therapy
extended into adulthood may be particularly beneficial for XLH patients that have particularly
burdensome dental disease. If management via traditional dental methods fails and one abscess
predicts the next, continuation of pharmaceutical therapy may be indicated for these particular
patients.
Our finding of higher odds of severe dental disease in males versus females is consistent
with clinical observation: male patients have been shown to have more extensive dental disease
than females (12). It is believed that the more severe dental phenotype in males can be at least
partially explained by the hemizygous nature of the disease allele in males, and that a more
striking gene dose effect is evidence for the teeth than the skeleton (12). This theory may also
explain our finding of a negative association between female sex and number of sites of
enthesopathy. The positive association between age and the two outcomes of interest may be
explained by the natural history of XLH: enthesopathy is known to be a morbidity of aging and
the more time that elapses, the more opportunity there is for dental abscess to occur. Although we
did not find proportion of adult life or proportion of total life to be important predictors of
enthesopathy, the finding that body mass index was positively associated with number of sites of
enthesopathy may be of clinical importance in that the increased load to insertion sites evident
with increasing BMI, may accelerate the disease process (13). Thus, greater body mass index, and
resultant increased load on the insertion sites may be an important factor in accelerating the
development of this complication. Our findings suggest that although pharmacological therapy
may not be effective for preventing enthesopathy, weight-loss interventions may be helpful in the
long-term.
In sum, we have assessed clinically significant outcomes of adult XLH that have not
previously been adequately explored. Although the cross-sectional nature of this study limits its
interpretation, the identification and use of a database for cumulative treatment history in adult
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patients with XLH is unique and informative. A randomized control trial directed toward adult
morbidities in XLH patients would be important to confirm the safety and efficacy of continued
treatment through adult years, however such a study is likely to require a lengthy follow up
period to capture sufficient for these age-dependent outcomes to develop.
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Table 1. Selected participant characteristics by proportion of adult Life with treatment a
0% of Adult life
with treatment b

Full sample b

8
31.8 (11.3)

0%<x<100% of
Adult life with
treatment b
27
40.7 (11.9)

100% of Adult
life with
treatment b
17
39.9 (18.4)

52
39.0 (14.4)

Age at onset of
treatment (yrs)

4.7 (8.3)

6.6 (11.5)

4.0 (6.9)

5.4 (9.7)

Yrs of treatment
>= age 18

1.6 (4.3)

6.4 (6.7)

20.9 (17.8)

10.5 (13.5)

Yrs of treatment
<18

14.0 (6.3)

13.5 (6.1)

14.5 (4.6)

13.9 (5.6)

Sex
Male
Female

3 (37.5)
5 (62.5)

9 (33.3)
18 (66.7)

6 (35.3)
11 (64.7)

18 (34.6)
34 (65.4)

BMI (kg/m2)

34.1 (11.2)

34.2 (10.4)

31.4 (5.9)

33.3 (9.2)

Body fat %

36.9 (11.1)

34.3 (11.7)

35.4 (12.4)

35.1 (11.5)

Height Z-score
>= -1.0
-1.1=<z<= -1.5
-1.6 -2.0
-2.1

0 (0.0)
1 (12.5)
2 (25.0)
5 (62.5)

4 (14.8)
2 (7.4)
2 (7.4)
19 (70.4)

0 (0.0)
3 (17.7)
2 (11.8)
12 (70.6)

4 (7.7)
6 (11.5)
6 (11.5)
36 (69.2)

Use of pain meds
Never
Less frequently
Weekly
Daily
> once/day

1 (12.5)
2 (25.0)
3 (37.5)
1 (12.5)
1 (12.5)

7 (25.9)
4 (14.8)
5 (18.5)
7 (25.9)
4 (14.8)

5 (31.3)
5 (31.3)
2 (12.5)
4 (25.0)
0 (0.0)

13 (25.5)
11 (21.6)
10 (19.6)
12 (23.5)
5 (9.8)

Previous no. of
osteotomies
none
1
2
>2

4 (50.0)
0 (0.0)
2 (25.0)
2 (25.0)

11 (40.7)
0 (0.0)
7 (25.9)
9 (33.3)

3 (17.7)
2 (11.8)
3 (17.7)
9 (52.9)

18 (34.6)
2 (3.9)
12 (23.1)
20 (38.5)

Characteristic
N
Age (yrs)

Mutation statusc
Not severe
Severe

1 (12.5)
6 (75.0)

9 (33.3)
17 (63.0)

3 (17.7)
11 (64.7)

13 (25.0)
34 (65.4)

1.63 (0.74)

1.85 (0.86)

1.82 (0.64)

1.81 (0.77)

No. of dental
abscesses
<=5
>5

2 (25.00)
6 (75.00)

9 (33.3)
18 (66.7)

9 (52.9)
8 (47.1)

20 (38.5)
32 (61.5)

PTHd

1068.5 (889.9)

985.6 (392.4)

1260.7 (751.8)

1088.3 (616.5)

FGF23

1976.5 (972.4)

6156.9
(140508.8)

4604.2 (7260.8)

5006.2 (11233.0)

No. of sites of
enthesopathy

a

Table values are mean ± SD for continuous variables and n (column %) for categorical
variables.
b
Numbers may not sum to total due to missing data, and percentages may not sum to 100% due
to rounding.
c
5 missing values for mutation severity were included in a “missing category”
d
PTH, area under the curve measure for PTH samples taken every 4 hours over a 26-hr period

2

Table 2. Age-adjusted and multivariate-adjusted multiple linear regression models of the
relationship between proportion of adult life with treatment, other predictors, and sites of
enthesopathy
Characteristic

Age-adjusted
β(SE)

β (SE)

P-value

0.80
0.99
0.96
0.68

-0.092 (0.23)
-0.0000015 (0.17)
Reference

0.69
1.0
0.90
0.50

0.033 (0.010)

<0.0010

0.023 (0.006)

<0.0010

-

-

Reference
-0.42 (0.16)

0.0080

-

-

0.034 (0.0090)

<0.0010

Mutation severitya
Not Severe
Severe

-

-

Reference
0.14 (0.18)

0.42

PTHb

-

-

0.00028 (0.00014)

0.051

Proportion of
treatment in
childhood
<0.80
≥0.80

-

-

0.30 (0.18)
Reference

0.10

Proportion of adult
life with treatment
0
0<x<1
1
Global p-value
P-value for trend

0.071 (0.27)
0.0040 (0.19)
Reference

Age (years)
Sex
Male
Female
Body mass index
(kg/m2)

a

P-value

Multivariate-Adjusted

Mutation analyses from 5 subjects were either not preformed or not definitive and were
included in a “missing” category
b
PTH, area under the curve measure for PTH samples taken every 4 hours over a 26-hr period

Table 3. Age-adjusted and multivariate-adjusted multiple linear regression models of the
relationship between proportion of total life with treatment, other predictors, and number
sites of enthesopathy
Characteristic

Age-adjusted
β(SE)

P-value

Multivariate-Adjusted
β (SE)

P-value

Proportion of total
life with treatment
0<=x<0.436
0.436<=0.588
0.588<=x<0.881
0.881<=x<=1.0
Global p-value
P-value for trend

0.012 (0.24)
0.19 (0.24)
-0.20 (0.24)
Reference

0.96
0.43
0.41
0.18
0.72

0.094 (0.21)
0.027 (0.23)
-0.050 (0.21)
Reference

0.66
0.91
0.81
0.90
0.54

Age (years)

0.031 (0.0060)

<0.0010

0.027 0(0.0060)

<0.0010

Sex
Male
Female

-

-

Reference
-0.42 (0.60)

0.012

-

-

0.030 (0.010)

0.0020

Mutation severitya
Not Severe
Severe

-

-

Reference
0.17 (0.18)

0.34

PTHb

-

-

0.00025 (0.00015)

0.10

Body mass index
(kg/m2)

a

5 missing values for mutation severity were included in a “missing category”
PTH, area under the curve measure for PTH samples taken every 4 hours over a 26-hr period

b

Table 4. Age-adjusted and multivariate-adjusted multiple logistic regression models of the
relationship between proportion of adult life with treatment, other predictors, and severity
of dental disease
Characteristic

Age-adjusted
OR (95% CI)

Multivariate-Adjusted

P-value

OR (95% CI)

P-value

Proportion of adult
life with treatment
0
0<x<1
1
Global p-value
P-value for trend

7.8 (0.85-71)
2.3 (0.51-11)
1.0

0.069
0.27
0.038
0.20

25 (1.2-520)
7.1 (0.88-58)
1.0

0.038
0.067
0.0080
0.066

Age (years)

1.1 (1.0-1.2)

0.0030

1.1 (1.0-1.2)

0.019

Sex
Male
Female

-

-

1.0
0.15(0.020-1.1)

0.061

Mutation severitya
Not Severe
Severe

-

-

1.0
3.9 (0.63-25)

0.14

Proportion of
treatment in
childhood
<0.80
≥0.80

-

-

7.2 (0.71-73)
1.0

0.10
-

a

5 missing values for mutation severity were included in a “missing category”

Table 5. Age-adjusted and multivariate-adjusted multiple linear regression models of the
relationship between proportion of adult life with treatment, other predictors, and sites of
enthesopathy
Characteristic

Age-adjusted
OR (95% CI)
P-value

Multivariate-Adjusted
OR (95% CI)
P-value

Proportion of total
life with treatment
0<0.436
0.436≤0.588
0.588≤0.881
0.881≤1.0
Global p-value
P-value for trend

8.8 (1.1-70)
5.6 (0.84-38)
2.0 (0.33-12)
1.0

0.040
0.075
0.45
0.012
0.046

31 (2.2-450)
25 (1.8-340)
4.8 (0.49-51)
1.0

0.012
0.017
0.20
0.0010
0.015

Age (years)

1.1 (1.0-1.1)

<0.0010

1.1 (1.0-1.2)

0.010

Sex
Male
Female

-

-

1.0
0.080 (0.0090- 0.71) 0.023

Mutation severity
Not Severe
Severe

-

-

1.0
5.2 (0.82-33)

*5 missing values for mutation severity were included in a “missing category”

0.080

